TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03809065
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin is a direct vasodilator and its main action is through venodilation. Nitroglycerin will be diluted by adding 3 mL (3 mg) to 47 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr to have a starting dose of 0.5 μg/Kg/min. The rate of nitroglycerin infusion will be 0.5-2 μg /kg/min .The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
Study: NCT02315430
Drug: Cabozantinib S-malate
Normalized name: Cabozantinib S-Malate
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03809065
Drug: Labetalol
Normalized name: Labetalol
DrugBank: Labetalol (DB00598)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Labetalol is an α and β - adrenergic receptors competitive antagonist. Labetalol will be diluted by adding 10 mL (50 mg) to 40 mL normal saline in a 50 mL syringe and will be infused after endotracheal intubation with a starting dose of 0.5 mL/Kg/ hr. The rate of Labetalol infusion will be 0.5-2 mg/kg/h.The infusion rate will be finely adjusted to maintain MAP around 55-65mmHg or till reaching adequate surgical field {defined as surgical field score (SFS) \<3}.
Study: NCT00751101
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
Study: NCT01206595
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 125 mg administered as a nerve block
Study: NCT00758303
Drug: Low Dose TRIA-662
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One Capsule 3 times a day
Study: NCT00758303
Drug: High Dose TRIA-662
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Capsules 3 times daily
Study: NCT03332004
Drug: Indocyanine Green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.25 mg /(kg BW) Indocyanine Green PULSION® - PULSION Medical Systems were administered intravenously
Study: NCT01595750
Drug: Roflumilast 500
Normalized name: ROFLUMILAST 500MCG TAB
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast 500 mcg , 12 weeks of treatment
Study: NCT02083250
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02083250
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02083250
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02083250
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01623778
Drug: Interferon Alfa-2a add on ADV
Normalized name: Interferon Alfa-2A
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon add on ADV for 48 weeks
Study: NCT01847144
Drug: Gliclazide 80mg OD
Normalized name: gliclazide 80 MG
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
Study: NCT01847144
Drug: Sitagliptin 100mg OD
Normalized name: SITagliptin 100 MG
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
Study: NCT00002466
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002466
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002466
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02379910
Drug: AM1030-CREAM or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: AM103 (DB05225)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00405808
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Once daily in the morning
Study: NCT00163488
Drug: Ciclesonide
Normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00325442
Drug: Oral treprostinil (UT-15C) sustained release tablets
Normalized name: treprostinil Extended Release Oral Tablet
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Study: NCT02909166
Drug: aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01421511
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion~* Linezolid Tablets, 600 mg, orally every 12 hours
Study: NCT00216606
Drug: topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01654497
Drug: Dexanabinol
Normalized name: Dexanabinol
DrugBank: Dexanabinol (DB06444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)~Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.~Dose Level 1: 2 mg/kg~Dose Level 2: 4 mg/kg~Dose Level 3: 8 mg/kg~Dose Level 4: 16 mg/kg~Dose Level 5: 24 mg/kg~Dose Level 6: 28 mg/kg~Dose Level 7: 36 mg/kg~Dose Level 8: 40 mg/kg~Dose Level 9: 44 mg/kg
Study: NCT01746992
Drug: Vincristine 1.4mg/m2
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: day 1
Study: NCT02078323
Drug: Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04330040
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet
Study: NCT03386513
Drug: IMGN632
Normalized name: IMGN632
DrugBank: IMGN632 (DB17337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD123-targeted ADC
Study: NCT03255434
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
Study: NCT03255434
Drug: Oxaliplatin LBM
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
Study: NCT01728324
Drug: Ribavirin: 24-week treatment
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 24 weeks of active treatment
Study: NCT01728324
Drug: Faldaprevir: 24-week treatment
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 weeks of active treatment
Study: NCT01728324
Drug: Ribavirin-placebo: 8-week treatment
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 weeks of placebo treatment
Study: NCT01728324
Drug: Faldaprevir-placebo: 8-week treatment
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks of placebo treatment
Study: NCT01728324
Drug: Faldaprevir: 16-week treatment
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 weeks of active treatment
Study: NCT01728324
Drug: Ribavirin: 16-week treatment
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 16 weeks of active treatment
Study: NCT00255372
Drug: PEG 4000 (Forlax®)
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
Study: NCT00255372
Drug: Lactulose active and Lactulose placebo
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
Study: NCT00168818
Drug: dabigatran etexilate
Normalized name: Dabigatran etexilate
DrugBank: Dabigatran etexilate (DB06695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily dose 150 mg once daily, half a dose on the day of surgery
Study: NCT02045277
Drug: IDP-118 Monad Taz Lotion
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT02232516
Drug: romidepsin
Normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02232516
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02561416
Drug: TAU
Normalized name: Tauvid
DrugBank: Flortaucipir F-18 (DB14914)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
Study: NCT00491114
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00168818
Drug: enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg once daily
Study: NCT00404781
Drug: cilostazol in addition to aspirin and clopidogrel
Normalized name: Cilostazol
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00003068
Drug: amifostine trihydrate
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003068
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003068
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03764215
Drug: Nilotinib 150 MG
Normalized name: nilotinib 150 MG
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 participants will receive an oral dose of 150mg Nilotinib once daily for 3 months (group 1). If this dose is tolerated another 10 participants will receive an oral dose of 300mg Nilotinib once daily (group 2) for 3 months.
Study: NCT00434850
Drug: Deoxyspergualin
Normalized name: Deoxyspergualin
DrugBank: Deoxyspergualin (DB12991)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
Study: NCT00434850
Drug: Sirolimus
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Maintenance immunosuppressive therapy
Study: NCT00434850
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maintenance immunosuppressive therapy
Study: NCT01680406
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01680406
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00845923
Drug: Civamide Patch
Normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
Study: NCT00480753
Drug: Nitroglycerin
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02140918
Drug: Fludrocortisone 100 μg
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 100 μg/day
Study: NCT02140918
Drug: Fludrocortisone 200 μg
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 200 μg/day
Study: NCT02140918
Drug: Fludrocortisone 400 μg
DrugBank: Fludrocortisone (DB00687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 400 μg/day
Study: NCT04405804
Drug: Ivabradine 5Mg Tab
Normalized name: IVABRADINE 5MG TAB
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial dose of ivabradine will be:~0.02 mg/kg/dose twice daily in patients between 6-12 months 0.05 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 2.5 mg/day in patients between 3-18 years with weight \> 40 kg During titration phase, the dose may be increased, maintained, reduced or discontinued in accordance with titration rules. The titration rules will be adjusted on the basis of age subset and of each patient's evaluation during the titration phase, whether or not the target heart rate is reached (HR ≥ 20% compared to baseline HR) and whether or not are present bradycardia (HR should be greater than predefined by a HR threshold per age subset) and/or bradycardia-related symptoms.~Maximum dose to be reached will be:~0.2 mg/kg/dose twice daily in patients between 6-12 months 0.3 mg/kg/dose twice daily in patients between 1-3 years and 3-18 years with a weight \< 40 kg 15 mg/day in patients between 3-18 years, weight \> 40 kg
Study: NCT00126542
Drug: erlotinib hydrochloride
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT06326840
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All participants were administered 1500 mg/day of metformin for eight weeks. The trial design is single-group with no masking.
Study: NCT00462696
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00462696
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00216021
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin 100 mg/m2 IV, day 1
Study: NCT02196142
Drug: Cortisol 20mg
Normalized name: Corticool
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: Cortisol 20mg
Study: NCT02196142
Drug: Placebo Mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Placebo Mannitol
Study: NCT03090620
Drug: Physostigmine
Normalized name: PHYSOSTIGMINE
DrugBank: Physostigmine (DB00981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of physostigmine bolus followed by an infusion
Study: NCT03090620
Drug: Lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of lorazepam bolus followed by normal saline infusion
Study: NCT03777579
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel at a starting dose of 125mg per square meter via IV infusion on Days 1, 8 of each 21-day cycle. Nab-Paclitaxel will be administered until disease progression or unacceptable toxicity.
Study: NCT00109317
Drug: Raptiva (efalizumab)
Normalized name: Raptiva
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00775359
Drug: Fenofibrate 160 mg tablets
Normalized name: Fenofibrate
DrugBank: Fenofibrate (DB01039)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03332667
Drug: Dinutuximab
Normalized name: Dinutuximab
DrugBank: Dinutuximab (DB09077)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dinutuximab is given intravenously on days 8-11 and 29-32 of therapy. Dinutuximab dose will be based on the dose level assigned at the time of patient registration.
Study: NCT03332667
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat will be given on day 0-13. Vorinostat dose will be based on the dose level assigned at the time of patient registration.
Study: NCT03332667
Drug: Sargramostim
Normalized name: Sargramostim
DrugBank: Sargramostim (DB00020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sargramostim (GM-CSF) will be given on day 8-17 at 250 mcg/m\^2
Study: NCT03332667
Drug: Potassium Iodide
Normalized name: Potassium Iodide
DrugBank: Potassium Iodide (DB06715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium iodide will be given by mouth at a dose of 6mg/kg 8-12 hours prior to infusion of 131I-MIBG on Day 1 and then 1mg/kg/dose by mouth starting 4-6 hours after completion of MIBG infusion and continuing every 4 hours on protocol days 1-7 and then 1mg/kg/dose by mouth once daily on protocol days 8-45
Study: NCT02482961
Drug: colistimethate sodium
Normalized name: Colistimethate Sodium
DrugBank: Colistimethate (DB01111)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
Study: NCT04271189
Drug: Metformin-Sitagliptin-Empaglifozin-Pioglitazone
Normalized name: metformin / pioglitazone
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg metformin (extended release) b.i.d., pioglitazone 15 mg b.i.d., sitagliptin 100 mg q.d., empaglifozin 10 mg q.d..
Study: NCT01140542
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500µg, once daily
Study: NCT01020292
Drug: Nelfinavir
Normalized name: Nelfinavir
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03408080
Drug: BHV-4157
Normalized name: BHV-5000
DrugBank: BHV-5000 (DB17817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BHV-4157 is a glutamate modulating drug that is being developed for eventual commercial use in the treatment of spinocerebellar ataxia (SCA). This is currently no approved medication indicated for SCA.
Study: NCT02242149
Drug: Diacerein
Normalized name: diacerein
DrugBank: Diacerein (DB11994)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
Study: NCT03670082
Drug: Lu AF35700
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Lu AF35700 single oral dose
Study: NCT03670082
Drug: Lu AF35700 iv
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg \[14C\]-Lu AF35700 (4.7 μCi/174 kBq) single intravenous micro-dose
Study: NCT02107391
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care Hormone Therapy as an Active Comparator
Study: NCT02107391
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard of Care Hormone Therapy as an Active Comparator
Study: NCT01809262
Drug: single dose of 5 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for inhalation
Study: NCT01809262
Drug: single dose of 40 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for inhalation
Study: NCT01809262
Drug: single dose of 20 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for inhalation
Study: NCT01809262
Drug: single dose of 2 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for inhalation
Study: NCT01809262
Drug: single dose of 10 mcg
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: solution for inhalation
Study: NCT01423240
Drug: Lurasidone 20 mg
Normalized name: lurasidone 20 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 20 mg once daily orally in the evening
Study: NCT01423240
Drug: Lurasidone 60 mg
Normalized name: lurasidone 60 mg oral tablet
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone 60 mg once daily orally in the evening
Study: NCT02003742
Drug: NX-1207
Normalized name: NX-1207
DrugBank: NX-1207 (DB05493)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
Study: NCT02003742
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
Study: NCT04429503
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreally (IVT) administered as a liquid formulation in a vial
Study: NCT04429503
Drug: High-dose aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreally (IVT) administered as a liquid formulation in a vial
Study: NCT00469144
Drug: Busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed Dose = 130 mg/m\^2 IV Daily Over Three Hours x 4 Days.~Adjusted Dose = 32 mg/m\^2 IV Over 2 Hours Test Dose x 1 Day.~Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%.
Study: NCT00469144
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/m\^2 IV Daily Over 1 Hour x 4 Days
Study: NCT00186940
Drug: Rasburicase
Normalized name: Rasburicase
DrugBank: Rasburicase (DB00049)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
Study: NCT01054404
Drug: Furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furosemide 0.3 mg/kg
Study: NCT03430882
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV